BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 20, 2015
View Archived Issues
AbbVie presents selective P2X3 receptor antagonists for pain management
Read More
La Jolla Pharmaceutical and Vanderbilt University form agreement for BMP type-I receptor inhibitors
Read More
The Wistar Institute and OncoCyte to develop diagnostic test for lung cancer
Read More
Amgen provides early preclinical data on TRPM8 antagonist for migraine
Read More
Ocular-selective oral VEGFR-2 inhibitors for wet AMD reported by Novartis
Read More
Edge Therapeutics reports topline phase I/II NEWTON trial data
Read More
Resunab granted FDA fast track status for the treatment of systemic sclerosis
Read More
Soligenix receives additional NIAID funding to advance heat stable ricin vaccine
Read More
FDA grants fast track designation to solithromycin for CABP
Read More
Vical's VL-2397 gets FDA QIDP designation
Read More
Alkeus provides update on ALK-001 for Stargardt disease
Read More
Long-term LATTE results show HIV suppression with two-drug cabotegravir plus rilpivirine regimen
Read More
Allergan patent reports formyl peptide modulators
Read More
GlaxoSmithKline discloses LRRK2 inhibitors
Read More
Boehringer Ingelheim divulges BTK inhibitors
Read More
TP Therapeutics patent details apoptosis inducers
Read More
Janssen terminates HMPL-507 agreement with Hutchison MediPharma
Read More
FDA awards rare pediatric disease designations to idebenone and drisapersen for DMD
Read More
Prostate cancer vaccine MVI-816 enters phase I/II trial in combination with pembrolizumab
Read More
CureXcell not expected to meet primary endpoint in pivotal venous leg ulcer trial
Read More
Vernalis discloses strategy for development of V-158866
Read More
EnGeneIC begins phase I Tailored-EDV trial in solid tumors
Read More
Vivozon starts phase II trial of analgesic candidate VVZ-149
Read More
PDE10A inhibitor TAK-063 enters phase II trial in schizophrenia
Read More
Threshold's TH-4000 enters phase II trial in squamous cell carcinoma
Read More
